US National Institutes of Health: Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)

This opportunity uses the U01 Research Project – Cooperative Agreements funding mechanism.

The goal of this scheme is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioural symptoms.

Funding & Duration

Application budgets are limited to USD $1M (approx. AUD $1.32M) in direct costs per year, and need to reflect the actual needs of the proposed project.

For Early Stage projects, the project period is limited to five years. For Late Stage projects, the project period is limited to three years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.